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ABSTRACT
Aims: Estimating the monetary value of the convenience of using influenza antivirals approved in
Japan from a patient perspective using a conjoint analysis.
Methods: An online survey (August 2020) was performed on individuals aged 20–64 years living in
Japan who had taken oral or inhalant antivirals for influenza treatment in the 2018/19 or 2019/20 sea-
sons. Efficacy and safety were assumed to be equivalent among the antivirals. The attributes for the
conjoint analysis included route (oral or inhalant), duration, frequency of administration, and out-of-
pocket expenses. A conditional logit model was applied as a baseline model. The monetary value of
each attribute was calculated by comparing the same utility of the linearly interpolated level of the
out-of-pocket attribute. Another survey to determine the experiences of the latest antiviral intake was
also conducted on the same respondents.
Results: Of the respondents, 1,550 were men and 1,587 were women. The monetary value for oral
antivirals was estimated to be higher, saving JPY 741 (USD 7.06, as of August 2020), compared with
inhalant. Regarding the length and frequency of administration, five days corresponds to an increase
of JPY 2,072, compared with one day, and twice a day corresponds to a JPY 574 increase compared to
once a day.
Conclusions: The results suggest that – among the antivirals approved in Japan – the monetary value
of the utility is the highest in the single dose oral antiviral, baloxavir marboxil (baloxavir). Although
the drug cost was highest in baloxavir among the brand antivirals, the difference in the value of utility
for influenza patient was estimated to be larger than the difference in the drug costs.
Limitations: Although individuals with diverse attributes from all over the country were included in
the survey, they are not necessarily a representative population of the Japanese society.
ARTICLE HISTORY
Received 27 November 2020
Revised 22 December 2020










I10; I1; I; I11; I12
Introduction
Each year, the influenza virus attacks 10–20% of people
worldwide1, resulting serious symptoms in 3 to 5 million2.
Although the duration of illness is only 1 to 2weeks, influen-
za’s burden of illness is the highest among all infectious dis-
eases due to its high incidence3. In addition, the current
COVID-19 pandemic has raised concerns about the possibility
of co-infection with influenza4. The Infectious Diseases
Society of America’s clinical guidelines for managing influ-
enza recommend the use of antiviral treatment5. Antiviral
treatment within 48 h of illness onset can shorten the dur-
ation of fever and other symptoms6,7. Moreover, antivirals
can reduce viral shedding, suggesting that they may lead to
suppression of transmission8.
There are two classes of antivirals available for influenza A
and influenza B. One is neuraminidase inhibitors (NAIs), such
as oseltamivir, zanamivir, peramivir, and laninamivir; these
inhibit the release of new virus from the cell surface. The
other is the cap-dependent endonuclease inhibitor baloxavir,
which inhibits the initiation of viral mRNA synthesis. Among
the series of antivirals, there are various dosage forms for
administration. Oral oseltamivir and inhaled zanamivir are
required twice daily for 5 consecutive days, and adherence –
which is an important factor of successful therapy – could
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influence the success of treatment9. Peramivir can be used
intravenously once daily or repeated administration.
Laninamivir and baloxavir are both single dose antivirals; the
former is inhaled, and the latter taken orally.
In Japan, baloxavir and a generic drug of oseltamivir were
approved in February and June 2018 respectively, and five
brand-name antivirals and the generic oseltamivir were used for
the treatment of 12.9 million people in the 2018/2019 season10.
Physicians most often choose a suitable drug for each patient;
however, we think that each patient has their own preference
for drug characteristics based on dosage forms. Quantification
of patient preferences for the drugs can be used to enhance
patient-centered care for influenza medication. However, to the
best of our knowledge, no study has explicitly investigated the
value of each antiviral based on patient preference.
This study aims to estimate the monetary value of the
convenience of antivirals approved in Japan from the per-
spective of patients using a conjoint analysis. We performed
the conjoint analysis on the combined dosage forms and
out-of-pocket cost of the drugs and a survey of recent expe-
riences of antiviral intake among Japanese adults who had
taken antivirals in the recent two seasons. Thus, we revealed
the differences in the values of patient preferences by the
dosage forms of antivirals.
Methods
Study design
We evaluated the monetary value of the convenience of anti-
virals for influenza treatment in patients through the conjoint
analysis based on an online survey. Conjoint analysis is an
established research method and is increasingly applied in
the medical field to assess value from the patient’s perspec-
tive11. In addition, good research practices for the conjoint
analysis have been identified by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)12. We
assumed that efficacy and safety is equivalent among the
antivirals in this survey. We also used a survey to examine
the most recent experiences of antiviral intake during the
period of taking antivirals and later.
This study was performed in accordance with the Ethical
Guidelines for Medical and Health Research Involving Human
Subjects by the Ministry of Education, Culture, Sports,
Science and Technology and the Ministry of Health, Labor
and Welfare13, and the checklist of good research practices
for the conjoint analysis by ISPOR12. Informed consent was
obtained from all respondents online. The study was
approved by the Ethics Committee of the Research Institute
of Healthcare Data Science (RI2020006) and registered with
the University Hospital Medical Information Network Clinical
Trial Registry (UMIN000041452).
Data source and participants
We used an online panel managed by INTAGE Inc. (Tokyo,
Japan) for the online survey. The panel included individuals
who had registered as members to participate in the online
surveys in advance. The respondents for the survey were
individuals aged 20–64 years living in Japan who had taken
oral or inhalant antivirals for influenza treatment in the
2018/19 or 2019/20 season. It is noted that the respondents
were limited to those who were treated with oral or inhalant
antivirals; those who had taken intravenous infusion antivi-
rals, which has also been available for influenza treatment,
were excluded. This is because we considered that intraven-
ous infusion antivirals may be used for hospitalized patients
or those with difficulty in oral ingestion. In the guidelines of
the Japanese Association for Infectious Diseases, it is sug-
gested that the peramivir, which is an intravenous infusion
antiviral, should be prescribed for outpatients when the
physician determine that intravenous infusion treatment is
applicable after careful consideration of the indications for
other antivirals, such as oral and inhaled antivirals14.
Consequently, patients treated with it may have different
characteristics from those who had taken oral or inhalant
antivirals. The age restriction was applied because people
outside the specified age range might have difficulty in
appropriately answering all the questions in both surveys of
the conjoint analysis and their experiences of antiviral intake.
We planned to include at least 3,000 individuals to obtain
robust results. Because these surveys included variety of
questions, the sample size was not set based on a calculation
of sample size power, but set at as many as possible within
the budget. The online survey was conducted in
August 2020.
Survey for the conjoint analysis
A conjoint analysis was performed to estimate the monetary
value of the convenience of antivirals. Table 1 describes the
attributes (dosage forms [administration route, duration of
administration, and frequency of administration per day] and
out-of-pocket expenses) and the levels for each attribute for
the analysis. The attributes and levels were selected through
a discussion with clinicians and an expert in medical eco-
nomics. Sixteen choice tasks were created from 72 possible
combinations based on an orthogonal design. A representa-
tive example of the choice task questions is shown in Figure
1. Respondents were provided with two options with ques-
tion sentences and were required to choose the preferable
one between them. The question sentences are as follows:
You are a patient with influenza and going to be treated
with an antiviral drug. Which of the following drugs do you
choose for the treatment? It takes 3 days to recover from the
influenza symptoms, such as fever and a sore throat, from
the initiation of the treatment with either drug. Note that
Table 1. Attributes and attribute levels in the survey for the conjoint analysis.
Attribute Level
Administration route Oral/inhalant
Duration of administration 1 day/5 days/10 days
Frequency of administration per day Once/twice/thrice
Out-of-pocket expenses JPY 3,000/JPY 6,000/JPY 9,000/
JPY 12,000
Abbreviation. JPY: Japanese yen ($1.00 corresponds to approximately JPY
105.00 as of August 2020).
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there are two types of administration routes in the treat-
ment options.
The administration routes were explained with pictures
along with the sentences. Each respondent completed 20
choice tasks.
Survey about the experiences of antiviral intake
We conducted a survey to determine the experiences of the
latest antiviral intake, including the period of taking the
drug, dosage form of the drug, whether all the drugs were
taken or not (percentage of drugs taken of all the prescribed
drugs), situation and feeling when taking the drugs, number
of days until breaking the fever, and number of days until
returning to usual life. The options for dosage form were
based on the available antivirals in Japan. These include
baloxavir: oral and single dose, oseltamivir: oral and twice
daily for 5 days (hereafter called “5-day dose”), laninamivir:
inhalant and single dose, and zanamivir: inhalant and 5-day
dose. The actual question sentences are listed in Table S1 of
the Supplementary material.
Statistical analysis
In conjoint analysis, the utility of each level of each attribute
was estimated. We applied a conditional logit model as a
baseline model for the conjoint analysis. The model eluci-
dates the hidden utility behind each level of each attribute
by inverse estimation, based on each choice between the
two options. In this model, the utility was assumed to be the
same among the respondents. The utility other than the
monetary attribute (out-of-pocket expenses) was converted
to monetary equivalent by comparing the same utility of the
linearly interpolated level of the monetary attribute.
Statistical significance was defined as p<.05. We also applied
the models with interaction terms, and these models were
stratified by groups based on the attributes of the respond-
ents for the analyses.
The answers to questions about experiences of antiviral
intake were tabulated by dosage forms of the latest antivirals
that the respondents took and the attributes of the respond-
ents. We also calculated the average and standard error (SE)
of the number of days until fever resolution and patients
returning to their usual life from the first medication based
on the answers. In these calculations, we considered “5 days
or longer” as 5 days, and “7 days or longer” as 7 days. We
excluded respondents who answered, “not sure”.
To support an interpretation of the results, we calculated
the productivity loss for each available antiviral in Japan by
applying the average number of days until returning to usual
life from initiation of the antiviral treatment (calculated
above) according to the Japanese Guideline for Cost-
Effectiveness Evaluation15. We assumed the monthly average
wage for each person to be Japanese Yen (JPY) 307,700,
which is the average wage across all industries, all ages, and
both genders obtained from the Japanese Basic Survey on
Wage Structure in 201916.
We used MS Excel 2016 (Microsoft, Redmond, WA) and R
software ver. 3.6.3 (The R Foundation for Statistical
Computing, Vienna, Austria) for the analyses.
Results
Respondents
We collected the answers from 3,137 individuals including
1,550 men (25 percentile, median, 75 percentile, and average± -
standard deviation (SD) of age: 32, 42, 52, and 42.1 ± 12.1 years)
and 1,587 women (32, 42, 51, and 41.9 ± 11.6 years; Table 2).
The number of respondents by attributes – including living pre-
fectures, marital status, occupation, and number of children liv-
ing together – are shown in Table S2.
Table 3 describes the number of respondents by dosage
forms as a combination of route and dose. The number of
respondents with the single dose inhalant antiviral was the
largest (916), followed by that with 5-day dose oral antiviral
(908), single dose oral antiviral (579), and 5-day dose inhalant
antiviral (266).
Monetary value for utility of antivirals based on the
conjoint analysis
The utility of each attribute and level based on the logit
model is shown in Figure 2. We found that higher
Figure 1. Example of choice task questions in the survey for the conjoint analysis.
246 N. HOSOGAYA ET AL.
out-of-pocket expenses, longer duration of administration,
and more frequent administration per day were associated
with larger negative utility; moreover, the impact of the
length of duration on the utility was shown to be greater
than that of the frequency. The utility was larger in the oral
than in the inhalant antiviral. The differences in the utility
between levels were statistically significant (p<.001) for
all attributes.
We estimated the monetary value for each attribute by
level, as shown in Table 4. The oral antiviral saves JPY 741 (US
Dollar 7.06, as of August 2020) compared with the inhalant.
Regarding the length and frequency of administration, com-
pared to 1 day, 5 days and 10 days correspond to a JPY 2,072
increase and JPY 4,172 increase, respectively; moreover, com-
pared to once a day, twice a day and thrice a day correspond
to a JPY 574 increase and JPY 1,129 increase, respectively.
We obtained the utility of attributes including the com-
bination of the administration route and duration of adminis-
tration (Figure S1A) and the combination of the duration and
frequency of administration (Figure S1B) from the model
with the minimum Akaike information criterion (AIC) and
second minimum AIC of all 64 models with possible combi-
nations, respectively. The superiority of oral to inhalant
tended to be reduced with an increase in duration (from
0.23 for 1 day to 0.11 for 10 days as utility; Figure S1A), and a
shorter duration tended to be preferred, regardless of the
frequency of administration (Figure S1B).
Almost the same tendency in the value of convenience
related to the dosage form was found regardless of the
attributes of respondents; however, some differences in the
size of the values were observed in some sub-groups strati-
fied by the attributes (Figure S2). The size of the values of
convenience related to the dosage forms was relatively simi-
lar among age and gender groups, but the utility value for
out-of-pocket expenses tended to be more negative in
groups of women aged 20–49 years compared with women
in other age bands and groups of men (Figure S2A). In analy-
ses for more stratified groups, the tendency of greater nega-
tive value of the utility for out-of-pocket expenses was
Table 2. Number of respondents by age and gender.
Age (5-year periods; years) Male Female Total
20–24 118 100 218
25–29 207 212 419
30–34 134 145 279
35–39 231 224 455
40–44 167 237 404
45–49 231 223 454
50–54 160 171 331
55–59 164 152 316
60–64 138 123 261
Total 1,550 1,587 3,137
Table 3. Number of respondents by dosage forms after cross-tabulation based
on answers to questions (Q5) “Which type of antiviral agent did you take the
last time?” and (Q6) “What kind of dosage did you take of (or how to use)
the antiviral agent?”
Oral drugs Inhalants Total
Once 579 916 1,495
Twice a day, 5 days 908 266 1,174
Not sure 229 113 342
Total 1,716 1,295 3,011
Note: Respondents who answered as “not sure” to Q5 are excluded. The ques-
tions and choices are shown in Table S1.
Figure 2. Utility of each variable based on the baseline model.
Table 4. Monetary value of each level of each attribute estimated by the
baseline model.
Estimate SE p-Value Monetary value (95% CI)
Inhalant 0.000
Oral 0.221 0.014 <.001 JPY 741 (652–830) discount
1 day 0.000
5 days 0.619 0.016 <.001 JPY 2,072 (1,967–2,177) increase
10 days 1.245 0.018 <.001 JPY 4,172 (4,056–4,288) increase
Once a day 0.000
Twice a day 0.171 0.017 <.001 JPY 574 (462–686) increase
Thrice a day 0.337 0.016 <.001 JPY 1,129 (1,021–1,237) increase
JPY 3,000 0.000
JPY 6,000 0.896 0.020 <.001
JPY 9,000 1.673 0.021 <.001
JPY 12,000 2.618 0.025 <.001
Abbreviations. JPY, Japanese yen ($1.00 corresponds to approximately JPY
105.00 as of August 2020); CI, confidence interval; SE, standard error.
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shown to be marked when the groups of women aged
20–49 years were married (Figure S2B) or had children living
together (Figure S2C). By stratifying respondents by the num-
ber of children living together, the value for oral to inhalant
tended to decrease, corresponding to the number of children
(Figure S2D). By stratifying occupations, a greater negative
value for an increase in out-of-pocket expenses tended to be
shown for self-employed individuals (including freelance and
professional workers), part-time employees, and house-wives/
husbands (Figure S2E). The value for oral to inhalant tended
to be greater in directors/managers and the self-employed;
relatively small in regular employees, civil servants, and con-
tractors; and negative in students (Figure S2E). We stratified
the respondents into three groups according to the level of
average salary in the prefectures where they lived17, and we
compared the values for the attributes among the groups.
The negative value for out-of-pocket expenses tended to be
higher in the lower average salary prefecture group; no such
tendency was seen for attributes related to dosage forms
(Figure S2F).
Experience of antiviral intake based on the survey
We examined the experience of antiviral intake – including
medication adherence, difficulty in taking the drug, feeling
of worry for vomiting or taking not enough the drug, and
number of days to break the fever and return to the usual
life – by attributes and dosage forms of the antivirals most
recently taken by the respondents. In respondents who took
the 5-day dose antivirals, the percentage of those who
answered that they took all drugs as instructed was 94.6%
for oral and 93.6% for inhalant. In those who did not take all
the drugs, the percentage of drugs they took was 70% or
larger in more than half of those with oral antivirals and 60%
or larger in more than half of those with inhalants
(Figure S3).
Figure 3. Difficulty in taking the drug (answer to Q 8-1: “Was it easy to take the antiviral that you took the last time?”) (A), and reasons for the difficulty (answer
to Q 8-2: “Why did you answer ‘Neither’ or ‘No’ to Q8-1 regarding the ease of taking the antiviral that you took the last time?”) by type of drug (B). Multiple choices
were allowed. Denominator: All respondents according to the type of dosage form of the drugs.
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Figure 3(A) illustrates the difficulty of taking the drug in
different dosage forms. The percentage of respondents who
answered “easy to take” was larger in those who took oral
drugs (87% for the single dose and 73% for the 5-day dose)
than those who used inhalants (72 and 63%, respectively),
and larger for those with a single dose than for those with a
5-day dose. The reasons for the answer “difficult to take” or
“neither” were similar between those with the same route of
administration, regardless of the dose; more common rea-
sons were “hard to swallow” for oral drugs and “cough or
choke” and “difficulty to use the inhaler kits” for inhalants
(Figure 3(B)).
The percentage of respondents who felt worried when
taking the drugs was lower in those taking oral antivirals
(11% for the single dose and 13% for the 5-day dose) than
those taking inhalants (28% for the single dose and 36% for
the 5-day dose), as well as in those with a single dose than
those with a 5-day dose (Figure 4(A)). Considering age and
gender, younger respondents tended to be associated with a
higher percentage of those who felt worried in both genders
(Figure 4(B)). This tendency was observed in both oral and
inhalant antivirals.
Considering the number of days to fever resolution from
initiation of the antiviral, the most frequent answer was
1 day in respondents with oral single dose antiviral, and
2 days in those with other antivirals (Figure 5). The number
of respondents who answered “not sure” was 55 for single
dose oral antiviral, 82 for 5-day dose oral antiviral, 98 for sin-
gle dose inhalant antiviral, and 19 for 5-day dose inhalant
antiviral. When comparing the demographics of the respond-
ents between those who answered, “not sure” and others,
the age was similar; average ± SD of age was 41.9 ± 11.9 and
41.9 ± 11.6 (p¼.50), but the percentage of woman was higher
in those who answered “not sure”, 59%, than others, 49%
(p<.01). After excluding the respondents who answered “not
sure”, the 25 percentile, median, 75 percentile, and
Figure 4. Feeling of worry about taking the drug (answer to Q 9: “When you were taking the antiviral for influenza the last time, were you worried that you would
vomit out the drugs or you did not take (inhale) enough of the drugs?”) by type of dosage form of the drugs (A) or by age and gender (B).
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average± SE of the number of days was 1, 2, 2, and
1.87 ± 0.04 days for single dose oral antiviral, 2, 2, 3, and
2.47 ± 0.04 days for 5-day dose oral antiviral, 1, 2, 3, and
1.99 ± 0.03 days for single dose inhalant antiviral, and 2, 2, 3,
and 2.40 ± 0.06 days for 5-day dose inhalant antiviral.
The most frequent answer for the number of days to
return to usual life (working or attending school) from initi-
ation of the antiviral was 5 days for all types of antivirals
(Figure 6). Respondents with single dose oral antiviral had
the highest percentage of those who answered 1–3 days
(27%) to the question among the antivirals (Figure 6). After
excluding patients who answered “not sure” (47and 60 indi-
viduals for single and 5-day dose oral antivirals, and 86 and
12 individuals for single and 5-day dose inhalant antivirals,
respectively), the average± SE of the number of days was 3,
5, 6, and 4.63 ± 0.07 days for single dose oral antiviral, 5, 5, 7,
and 5.22 ± 0.05 days for 5-day dose oral antiviral, 4, 5, 6, and
4.97 ± 0.05 days for single dose inhalant antiviral, and 5, 5, 6,
and 5.20 ± 0.09 days for 5-day dose inhalant antiviral. Notably
the age was similar between the respondents who answered,
“not sure” and others (41.4 ± 11.4 and 42.0 ± 11.7, p¼.20),
while the percentage of woman was higher in those who
answered “not sure” than others (60 and 49%, p<.01).
Discussion
We estimated the monetary value of the convenience of
antivirals based on the conjoint analysis. Higher out-of-
pocket expenses, longer duration of administration, and
more frequent administration per day were shown to be
associated with lower utility value. The impact on the value
was greater based on the duration compared with the fre-
quency per day. These results are reasonable when consider-
ing the convenience of the patients. In addition, results of
the survey about the experience of antiviral intake in this
study suggested that longer duration with more frequent
administration is associated with difficulty and feeling of
worry to take the drugs even between the same routes of
administration. The likely reason for these survey results is
the number of times patients experienced difficulty and feel-
ings of worry. The differences in the devices to inhale the
drugs for different dosage forms may also be associated with
the results.
When comparing oral and inhalant antivirals, a higher
value of convenience was estimated in oral administration by
conjoint analysis (Table 4). This result is consistent with the
results regarding the difficulty and feelings of worry about
Figure 5. Number of days to fever resolution from initiation of the antivirals (answer to Q 10: “When you were taking the antiviral for influenza the last time, how
long did it take to break your fever after the first dose?”) by dosage form of the drugs identifying the percentages of respondents excluding those who answered
“not sure” for each answer. N: number of respondents excluding “not sure” (oral, single dose: 55; oral, 5-day dose: 82; inhalant, single dose: 98, and inhalant, 5-day
dose: 19).
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Figure 6. Number of days to return to the usual life from initiation of the antivirals (answer to Q 11: “When you were taking the antiviral for influenza the last
time, how long did it take to return to your usual life (working or attending school) after the first dose?”) by type of dosage form of the drugs identifying the per-
centages of respondents excluding those who answered “not sure” for each answer. N: number of respondents excluding “not sure” (oral, single dose: 47; oral, 5-
day dose: 60; inhalant, single dose: 86, and inhalant, 5-day dose: 12).
Table 5. Estimated total cost of the drug, utility, and productivity loss for influenza per patient for available antivirals in Japan.
Baloxavir marboxil Oseltamivir Oseltamivir (generic) Laninamivir Zanamivir
Dosage form Oral, single dose Oral, 5-day dose Inhalant, single dose Inhalant, 5-day dose
1) Given: drug cost per
patient (adult)
JPY 4,878 JPY 2,672 JPY 1,281 JPY 4,359 JPY 2,882
2) Total value of utility
estimated by
conjoint analysis
JPY 3,387 JPY 741 JPY 741 JPY 2,646 JPY 0
Value of oral compared
with inhalant
JPY 741 JPY 741 JPY 741 JPY 0 JPY 0
Value of 1 day dosing
compared with the 5-
day dose
JPY 2,072 JPY 0 JPY 0 JPY 2,072 JPY 0
Value of once a day
compared with twice a day
JPY 574 JPY 0 JPY 0 JPY 574 JPY 0
3) Consideration:
productivity loss
JPY 46,816 JPY 52,812 JPY 52,812 JPY 50,227 JPY 52,572
Average number of days to
return to usual life (working
or attending school) from
the survey
4.63 5.22 5.22 4.97 5.20
Productivity loss per day JPY 10,116 JPY 10,116 JPY 10,116 JPY 10,116 JPY 10,116
Total cost of influenza JPY 48,306 JPY 54,743 JPY 53,352 JPY 51,940 JPY 55,454
1)  2) þ 3)
Difference from
baloxavir marboxil
– JPY 6,436 JPY 5,045 JPY 3,634 JPY 7,148
Note: The drug cost of baloxavir marboxil was calculated for the prescription dosage of 40mg (for patients weighing <80 kg) based on the average body
weight of the Japanese people. All drugs not specified as “generic” are branded drug.
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taking the drugs in the survey18. Moreover, the answer about
the feelings of worry for inhalants is consistent with the
complaints often made by patients stating that they are not
sure if they could inhale the drugs properly in clinical
practice19,20.
The trend in the value for convenience was not much dif-
ferent between all respondents and those in each sub-group
stratified by the attributes of the respondents; however, the
size of the value was diverse among the sub-groups (Figure
S2). A reduction in the value for oral associated with the
number of children living together is probably because the
inhalants are often used for children in Japan21, which means
that parents are used to the inhalants. The relatively lower
and negative value for oral to inhalant in the respondents in
their 20 s and students, respectively, may also be for the
same reason; they easily remember the experiences when
they were children. We found differences in the size of utility
of the dosage forms and out-of-pocket expenses among
occupations of the respondents. In regular employees, direc-
tors/managers, and civil servants, which could be considered
to have higher income and/or employment stability, lower
negative values of out-of-pocket expenses were shown in all
three categories of occupations; however, the size of the
value of dosage forms differed among the occupations.
These results suggest that the value of convenience related
to dosage forms may be associated with factors other than
the amount of income and employment stability. Regarding
the amount of income, no association was observed between
the value of dosage forms and level of salary in the
prefectures.
Adherence of more than 90% was indicated for drugs
with a 5-day dose in the survey. This is rather high, com-
pared with that of oseltamivir, which is reported as ranging
from 30 to 88% for all and 70–80% for most studies in an
existing systematic review including both treatment and
prophylaxis for influenza22; and as 78.9% in a study based on
a survey23. Considering the reported number of days until
fever resolution, about 2 days in this survey, most respond-
ents were supposed to continue taking the medication after
fever resolution. In Japan, people developing influenza are
suspended from the workplace or school until 2 or 3 days
after fever resolution24,25. Therefore, it is reasonable that
patients continue the medication during recuperation at
home, even after fever resolution. Another possible reason
for the high compliance is the respondents’ characteristics;
people who answer the survey may tend to be earnest and
take the drugs properly. If so, adherence in this study could
be higher than that in Japanese patients. As described
above, the results regarding the difficulty and feeling of
worry when taking the drug could be considered consistent
with the results of the conjoint analysis. In addition, we
found that younger respondents tended to have feelings of
worry, probably due to the amount of experience in the
past; generally, older people have more opportunities to
take drugs26.
The average number of days until fever resolution was
shorter in single dose antivirals than in 5-day dose antivirals
in both oral and inhalant, and also that was shorter in single
dose oral administration than in single dose inhalant antiviral
(Figure 5). This result is similar to that of a 2020 Japanese
multicenter observational study that included 295 patients
aged 0–91 years old27. In that study, the average ± SD time
to the alleviation of the fever was reported to be
1.94 ± 0.09 days for 111 patients prescribed baloxavir (a single
dose oral antiviral) and 2.35 ± 0.08 days for those prescribed
NAIs (oseltamivir: 74 patients, zanamivir: 24 patients, perami-
vir: 4 patients, and laninamivir: 77 patients), and the differ-
ence was statistically significant (p¼.002). Shorter time to
fever resolution in baloxavir (median [interquartile range]: 1.0
[1.0–2.0] days) than in laninamivir (2.0 [1.5–3.5] days, p¼.032)
was also reported in another observational study including
43 adult patients treated with baloxavir (14 patients), lanina-
mivir (16 patients), or oseltamivir (13 patients) 28. The median
time for baloxavir was also shorter than that for oseltamivir
(3.0 [1.0–3.0] days), although the difference was not statistic-
ally significant (p¼.067).
The time to return to usual life was also shorter in
respondents with the single dose oral antiviral than in those
with others in our study (Figure 6). Because we did not
examine factors indicating the severity of influenza in this
study, the comparison while adjusting for confounding fac-
tors could not be conducted for the differences in the num-
ber of days among different dosage forms. Considering the
situation in Japanese clinical practice, it is unlikely that balox-
avir is more often prescribed for patients who have mild
symptoms and/or are easy to recover than other antivirals.
We should also consider the possibility of the effect of recall
bias; patients who took antivirals with shorter duration of
administration might recall the length of duration to be
shorter. However, the duration until returning to usual life
was not so different between inhalants with different dura-
tions of administration.
To interpret the results, we calculated the cost for influ-
enza per patient for available antivirals as follows (Table 5).
Here, we assumed that there were no confounding factors
for treatment choice among respondents:
total drug cost29,30 – monetary value of the utility of convenience
estimated by the conjoint analysisþproductivity loss estimated
based on the survey.
The drug cost of baloxavir was calculated with the pre-
scription dosage at 40mg based on the average body weight
of Japanese individuals31. The dosage increases to 80mg for
patients weighing more than 80 kg. The cost, calculated as
drug cost – monetary value of utility
was JPY 1,491 for baloxavir, which is lower than that of
other brand drugs (JPY 1,931 for oseltamivir, JPY 1,713 for
laninamivir, and JPY 2,882 for zanamivir) but higher than
that of generic oseltamivir, JPY 540. The cost, after including
the productivity loss, was the lowest for baloxavir (JPY
48,306) among all the antivirals, including generic oseltami-
vir, JPY 53,352.
This study has several limitations. First, it was based on an
online survey of internet panels, who were registered as
members to participate in online surveys in advance, pro-
vided by a survey company. Although we included
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respondents with a wide range of attributes – men and
women aged 20–64 years from all over the country – they
are not necessarily a representative population of Japanese
society. In fact, when comparing the age distribution
(20–60s) between the respondents of this study and the
whole population of patients with influenza in Japan based
on the national surveillance32, the percentage of the
respondents in the 20 s was higher (20 vs. 16%, p<.01), and
that in the 40 s and the 60 s was lower (27 vs. 30%, p¼.03,
and 8 vs. 12%, p¼.02, respectively) in the respondents of this
study than that in the whole population. The difference
might be caused by the characteristics of the survey using
internet. Second, reliability of the study results depends on
whether the respondents accurately understood and to what
extent they veraciously answered the questions. Particularly
in the survey about the latest antiviral intake, we should con-
sider the possibility that the respondents remembered con-
comitant drugs taken as needed, other than the antivirals, or
that they were influenced by their recall bias. Third, we tar-
geted people who had taken antivirals for influenza for not
only the survey about the experience but also the conjoint
analysis. Although, for the conjoint analysis, it could be
another option that not to limit to those who had experi-
ence in taking the antivirals, we considered that the people
who had experiences in taking antivirals were supposed to
give more reliable answers when selecting their preference
from two options of choice tasks because they could
imagine the actual treatment. It should be noted that in
Japan, most patients with influenza received antivirals as
treatment33; therefore, we considered that limiting the sam-
ple to them would not have a significant negative effect on
this study’s generality. Finally, we showed the results from
the survey about the experiences of antiviral intake based on
the assumption of no confounding effects between the
choice of the antivirals and answers to the questions; thus,
we did not adjust for confounding factors in this analysis.
Conclusions
Higher monetary value of convenience was estimated in oral
antivirals than inhalants based on the conjoint analysis.
Higher value was also estimated for those with single dose
intake compared with those with a 5-day dose, in both oral
and inhalant antivirals. Among the brand antivirals approved
in Japan, the monetary value of the utility of baloxavir was
suggested to be the highest and the difference in the value
of utility was larger than the difference in drug costs with all
the brand antivirals. Moreover, the monetary value of utility
is lower than the difference in drug cost between baloxavir
and generic drug of oseltamivir. When assuming that there
were no confounding factors for treatment choice among
respondents, the total cost for influenza per patient – includ-
ing productivity loss calculated based on the survey – was
estimated to be the lowest in baloxavir among all antivirals,
including generic oseltamivir. From the perspective of
patient-centered care, a treatment choice considering the
convenience for each patient is important. Thus, our results
will help physicians choose antivirals for influenza patients.
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